Grab These 3 Healthcare Mutual Funds for Steady Returns

Investors often rely on the healthcare sector to safeguard their investments. This is because healthcare services do not see their demand varying too much with respect to market conditions and thus offer sufficient protection to the capital invested. Many pharmaceutical companies also offer regular dividends. Companies that consistently pay out dividends are financially stable and generate steady cash flows, irrespective of market conditions. Mutual funds are the perfect choice for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight.Below, we share with you three top-ranked Healthcare mutual funds, namely Fidelity Select Health Care FSPHX, Vanguard Health Care Fund VGHCX and Fidelity Advisor Biotechnology Fund FBTIX. Each has earned a Zacks Mutual Fund Rank #1 (Strong Buy) and is expected to outperform its peers in the future. Investors can click here to see the complete list of funds.Fidelity Select Health Care seeks to invest the majority of its net assets in common stocks of domestic and foreign issuers primarily engaged in the design, manufacture, or sale of products or services used for or in connection with health care or medicine. FSPHX’s investments are mostly based on a fundamental analysis of companies and their market position with respect to broader economic conditions.Fidelity Select Health Care has three-year annualized returns of 2.5%. As of May 2024, FSPHX held 92 issues, with 10.9% of its assets invested in Boston Scientific.Vanguard Health Care Fund invests the majority of its net assets in the common stocks of foreign and domestic companies. These companies are engaged in the development, production, or distribution of products and services related to pharmaceutical and medical supply companies, as well as businesses that operate hospitals and other healthcare facilities.Vanguard Health Care Fund has three-year annualized returns of 6.8%. VGHCX has an expense ratio of 0.35% compared to the category average of 1.04%.Fidelity Advisor Biotechnology Fund invests the majority of its net assets in securities of companies principally engaged in the research, development, manufacture and distribution of various biotechnological products, services and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. FBTIX’s investments are mostly based on a fundamental analysis of companies and their market position with respect to broader economic conditions.Fidelity Advisor Biotechnology Fund has three-year annualized returns of 6.8%. Eirene Kontopoulos has been the fund manager of FBTIX since July 2018.To view the Zacks Rank and the past performance of all Healthcare mutual funds, investors can click here to see the complete list of healthcare mutual funds.Want key mutual fund info delivered straight to your inbox?Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>Free Report: 5 Clean Energy Stocks with Massive UpsideEnergy is the backbone of our economy. It’s a multi-trillion dollar industry that has created some of the world’s largest and most profitable companies.Now state-of-the-art technology is paving the way for clean energy sources to overtake “old-fashioned” fossil fuels. Trillions of dollars are already pouring into clean energy initiatives, from solar power to hydrogen fuel cells.Emerging leaders from this space could be some of the most exciting stocks in your portfolio.Download Nuclear to Solar: 5 Stocks Powering the Future to see Zacks’ top picks free today.View All Zacks #1 Ranked Mutual FundsWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Get Your Free (FSPHX): Fund Analysis Report Get Your Free (VGHCX): Fund Analysis Report Get Your Free (FBTIX): Fund Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks